U.S. markets close in 4 hours 47 minutes
  • S&P 500

    4,274.70
    +0.66 (+0.02%)
     
  • Dow 30

    33,901.42
    -78.90 (-0.23%)
     
  • Nasdaq

    12,954.71
    +16.59 (+0.13%)
     
  • Russell 2000

    1,991.89
    +4.58 (+0.23%)
     
  • Crude Oil

    90.40
    +2.29 (+2.60%)
     
  • Gold

    1,776.30
    -0.40 (-0.02%)
     
  • Silver

    19.67
    -0.06 (-0.28%)
     
  • EUR/USD

    1.0137
    -0.0043 (-0.43%)
     
  • 10-Yr Bond

    2.8510
    -0.0420 (-1.45%)
     
  • GBP/USD

    1.2007
    -0.0045 (-0.37%)
     
  • USD/JPY

    135.1350
    +0.0450 (+0.03%)
     
  • BTC-USD

    23,404.82
    +10.03 (+0.04%)
     
  • CMC Crypto 200

    557.78
    +0.05 (+0.01%)
     
  • FTSE 100

    7,527.15
    +11.40 (+0.15%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

Clovis Shares Jumps After Highlighting Data From Targeted Radiotherapy Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Clovis Oncology Inc (NASDAQ: CLVSannounced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).

  • Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated a manageable safety profile and encouraging evidence of activity, including a confirmed RECIST partial response in one patient.

  • A confirmed RECIST partial response was reported in one heavily pre-treated patient in the 3.7 GBq dose cohort who completed six administrations of 177Lu-FAP-2286.

  • Related: Clovis Oncology Targeted Cancer Radiation Therapy Shows Greater Tumor Inhibition.

  • A decrease in the serum tumor marker carcinoembryonic antigen was also observed in the patient over the 177Lu-FAP-2286 administration.

  • Recruitment for the third dose cohort (7.4 GBq) is ongoing.

  • The company updated the investigator-initiated Phase 1 study of FAP-2286 labeled with gallium-68 (68Ga-FAP-2286) as a novel imaging agent to identify metastatic cancer in patients with solid tumors.

  • The safety and tumor uptake of the imaging agent 68Ga-FAP-2286 is being evaluated, with plans for Phase 2 expansion cohorts in multiple tumor types to initiate in Q4 2022.

  • Price Action: CLVS shares are up 11.70% at $0.90 during the premarket session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.